An Open Label, Phase I Study To Determine the Safety, Tolerability and Pharmacodynamics of Multiple Ascending Doses of PMZ-1620 in healthy male volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2017
At a glance
- Drugs PMZ 1620 (Primary)
- Indications Cerebrovascular disorders; Neurodegenerative disorders; Solid tumours
- Focus Adverse reactions
- Sponsors Pharmazz
- 09 Feb 2017 According to a Spectrum Pharmaceuticals media release, first patient has been dosed in the study.
- 08 Dec 2016 New source identified and integrated Clinical Trials Registry - India : CTRI/2016/11/007509
- 08 Dec 2016 New trial record